A series of Phase I to III trials of this drug and a related drug, AKCEA-APOCIII-LRX, have shown decreases of both apoC-III production and TAG concentrations in preclinical models and healthy volunteers (Graham et al. 2013) and in patients with familial chylomicronemia syndrome (FCS) (Gaudet et al. 2014, 2017) and those with hypertriglyceridaemia (Alexander et al. 2019; Gaudet et al. 2015; Ionna Gouni-Berthold et al. 2018). This evidence concerns the gene APOC3 and hypertriglyceridemia.